Related Experiment Videos
[Aspirin vs ticlid and their combination in patients with acute myocardial infarction]
Insights
Tiklid effectively reduces platelet aggregation in myocardial infarction patients, outperforming aspirin. Combination therapy with Tiklid and aspirin offers superior platelet inhibition but increases hemorrhagic risks.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Myocardial infarction (MI) necessitates therapies to prevent platelet aggregation.
- Conventional treatments include heparin and antianginal drugs.
Purpose of the Study:
- To compare the efficacy of Tiklid (ticlopidine) and aspirin in inhibiting ADP-induced platelet aggregation in MI patients.
- To evaluate the combined effect of Tiklid and aspirin on platelet aggregation and clinical outcomes.
Main Methods:
- 28 MI patients were randomized into three groups receiving conventional therapy plus aspirin, Tiklid, or Tiklid + aspirin.
- Adenosine diphosphate (ADP)-induced platelet aggregation was measured.
- Clinical outcomes including postinfarction angina and hemorrhagic complications were assessed.
Main Results:
- Tiklid demonstrated superior inhibition of platelet aggregation compared to aspirin at days 7 and 21 post-MI.
- The combination of Tiklid and aspirin provided greater platelet aggregation suppression than monotherapy.
- The combination therapy showed insignificant improvement in postinfarction angina but a high incidence of hemorrhagic complications.
Conclusions:
- Tiklid is a more effective antiplatelet agent than aspirin in MI patients.
- Combination therapy with Tiklid and aspirin enhances antiplatelet effects but elevates bleeding risk.
- Careful consideration of the risk-benefit profile is crucial when using combination therapy.
Abstract:
ADP-induced platelet aggregation was studied in 28 patients with myocardial infarction randomized, at admission, into three groups. Conventional therapy with heparin and antianginal drugs was combined with aspirin (250 mg/day, n = 9), tiklid (500 mg/day, n = 9), tiklid (500 mg/day) + aspirin (250 mg/day, n = 10) in group 1, 2 and 3, respectively. Tiklid diminished platelet aggregation more effectively than aspirin on the disease day 7 and 21. Tiklid + aspirin combination suppresses platelet aggregation more than monotherapy with either of the drugs, provides insignificant attenuation of postinfarction angina but is associated with a high risk of hemorrhagic complications.